Nuzenio

Reclaim Phase

Reclaim Phase news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 7 latest news signals 7 publisher sources 100/100 entity strength

Latest news

Once-weekly pemvidutide begins phase 3 trial for MASH - Managed Healthcare ExecutiveManaged Healthcare Executive · Mon, 10 Aug 2026 20:55:22 GMTFDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership - Applied Clinical Trials OnlineApplied Clinical Trials Online · Fri, 07 Aug 2026 13:58:37 GMTAltimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH - The Manila TimesThe Manila Times · Mon, 03 Aug 2026 12:20:58 GMTAltimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder - Yahoo FinanceYahoo Finance · Tue, 28 Jul 2026 07:00:00 GMTAltimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder - Slideshow (NASDAQ:ALT) 2026-07-28 - Seeking AlphaSeeking Alpha · Tue, 28 Jul 2026 07:00:00 GMTAltimmune Announces Positive Phase 2 RECLAIM Trial Results for Pemvidutide in Treating Alcohol Use Disorder - Kalkine MediaKalkine Media · Tue, 28 Jul 2026 07:00:00 GMTUpdated: Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism - Endpoints NewsEndpoints News · Tue, 28 Jul 2026 07:00:00 GMT

Timeline

Mon, 10 Aug 2026 20:55:22 GMTOnce-weekly pemvidutide begins phase 3 trial for MASH - Managed Healthcare Executive
Fri, 07 Aug 2026 13:58:37 GMTFDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership - Applied Clinical Trials Online
Mon, 03 Aug 2026 12:20:58 GMTAltimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH - The Manila Times
Tue, 28 Jul 2026 07:00:00 GMTAltimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder - Yahoo Finance
Tue, 28 Jul 2026 07:00:00 GMTAltimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder - Slideshow (NASDAQ:ALT) 2026-07-28 - Seeking Alpha
Tue, 28 Jul 2026 07:00:00 GMTAltimmune Announces Positive Phase 2 RECLAIM Trial Results for Pemvidutide in Treating Alcohol Use Disorder - Kalkine Media

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Reclaim Phase.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

7 distinct publisher/source names are currently connected to this entity page.